Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Serological paroteomic biomarkers for monitoring liver fibrosis regression in on-treatment hepatities b patients

ABSTRACT: Paired serological proteomes from CHB patients undergoing short-term and long-term anti-viral treatment were profiled using PRM-based proteomics technology.The serological proteomic landscapes following AVT were systematically analyzed and compared between fibrosis regressors and non-regressors.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Cell, Blood Plasma

DISEASE(S): Hepatitis B

SUBMITTER: Mengyang Zhang

LAB HEAD: Hong You

PROVIDER: PXD063833 | Pride | 2025-08-25

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	90942-100_Slot2-5_1_9629.d.zip	Other
	90942-101_Slot2-6_1_9631.d.zip	Other
	90942-102_Slot2-7_1_9633.d.zip	Other
	90942-103_Slot2-8_1_9634.d.zip	Other
	90942-104_Slot2-9_1_9635.d.zip	Other

Items per page:

1 - 5 of 171

Publications

Serological proteomic characterization for monitoring liver fibrosis regression in chronic hepatitis B patients on treatment.

Zhang Mengyang M Chen Shuyan S Wu Xiaoning X Zhou Jialing J Wang Bingqiong B Meng Tongtong T Hua Rongxuan R Sun Yameng Y You Hong H Chen Wei W

Nature communications 20250819 1

Longitudinal serological proteomic dynamics during antiviral therapy (AVT) in chronic hepatitis B (CHB) patients with liver fibrosis remain poorly characterized. Here, using four-dimensional data-independent acquisition mass spectrometry (4D-DIA-MS), paired liver biopsy (LBx)-proven serum samples from 130 CHB liver fibrosis patients undergoing short-term (78 weeks) or long-term (260 weeks) AVT are analyzed. Our findings show that prolonged AVT drives progressive serological proteomic remodeling ...[more]

PMID: 40830346

Similar Datasets

Serological paroteomic biomarkers for monitoring liver fibrosis regression in on-treatment hepatities b patients

Project description:Paired serological proteomes from CHB patients undergoing short-term and long-term anti-viral treatment were profiled using 4D-DIA-based proteomics technology.The serological proteomic landscapes following AVT were systematically analyzed and compared between fibrosis regressors and non-regressors.

2025-08-25 | PXD059174 | Pride

Chronic allergen exposure drives accumulation of long-lived IgE plasma cells in the bone marrow, giving rise to serological memory

Project description:Summary: Long-lived IgE plasma cells reside in the bone marrow of allergic mice and atopic humans, confer IgE serological memory and produce allergen-specific IgE that can drive anaphylaxis. Abstract: Immunoglobulin E (IgE) plays an important role in allergic diseases. Nevertheless, the source of IgE serological memory remains controversial. We re-examined the mechanism of serological memory in allergy using a dual-reporter system to track IgE plasma cells (PCs) in mice. Short-term allergen exposure resulted in the generation of IgE plasma cells that resided mainly in secondarylymphoid organs and produced IgE that was unable to degranulate mast cells. In contrast, chronic allergen exposure led to the generation of long-lived IgE plasma cells that were primarily derived from sequential class switching of IgG1, accumulated in the bone marrow (BM) and produced IgE capable of inducing anaphylaxis. Most importantly, IgE plasma cells were found in the BM of human allergic, but not non-allergic donors, and allergen-specific IgE produced by these cells was able to induce mast cell degranulation when transferred to mice. These data demonstrate that longlived IgE BMPCs arise during chronic allergen exposure and establish serological memory in both mice and humans.

2019-11-16 | GSE140435 | GEO

PBC DIGE - Analyzing serological differences between AMA positive and negative PBC using DIGE

Project description:Analyzing serological differences between AMA positive and negative PBC using DIGE

2014-11-27 | PXD001152 | Pride

Serological mechanisms driving cardiotoxicity in COVID-19

Project description:Serological mechanisms driving cardiotoxicity in COVID-19

| PRJNA855896 | ENA

Evaluation of novel serological markers for early diagnosis of colorectal neoplasia

Project description:Interventions: Group 1: Observational study: Participants in the colorectal cancer screening program, who undergo colonoscopy and a serological examination. Primary outcome(s): sensitivity and specificity of the three serological tests at predefined cutpoints with colonoscopy as gold standard for ascertainment of colorectal neoplasia Study Design: Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: diagnostic

| 2429165 | ecrin-mdr-crc

Proteomics Landscape of Diverse Serological Patterns in COVID-19

Project description:Serological test is a powerful tool to help clinicians assess the patients’ status during COVID-19 treatment. Highly diverse serological outcomes as exemplified by the negative or overly high IgG and IgM expressions are frequently reported but never elucidated interpreted with molecular insights. We classed a patient cohort (N=144) into four groups based on their longitudinal serological patterns and compared their differences in clinical indicators across a two-year manifestation. Thereafter, four patients from each group (N=16) with 111 serum samples collected during the 10 weeks since disease onset were enrolled for proteomic analyses.

2023-01-27 | PXD039722 |

Serological autoantibody profiling of emmetropic controls and highly myopic patiens

Project description:Serological autoantibody profiling of emmetropic controls and highly myopic patiens

| PRJNA926314 | ENA

Proteomics and bioinformatics investigations to improve serological diagnosis of canine brucellosis

Project description:Brucella canis is pathogenic for dogs and humans. Serological diagnosis is a cost-effective approach for disease surveillance, but a major drawback of current serological tests is the cross-reactivity with other bacteria that results in false positive reactions, and development of indirect tests with improved sensitivity and specificity remain a priority. A western blotting assay was developed to define the serum antibody patterns associated to infection using a panel of positive and negative dog sera. B. canis positive sera recognized immunogenic bands ranging from 7 to 30 kDa that were then submitted to ESI–LC-MS/MS and analyzed by bioinformatics tools. A total of 398 B. canis proteins were identified. Bioinformatics tools identified 16 non cytoplasmic immunogenic proteins predicted as non-homologous with the most important Brucella cross-reactive bacteria and 9 B. canis proteins non-homologous to B. ovis; among the latter, one resulted non-homologous to B. melitensis. The western blotting test developed was able to distinguish between infected and non-infected animals and may serve as confirmatory test for the serological diagnosis of B. canis. The mass spectrometry and in silico results lead to the identification of specific candidate antigens that pave the way for the development of more accurate indirect diagnostic tests

2023-10-24 | PXD042682 | Pride

Epigenetic regulation of the homeobox gene MSX1 associates with platinum resistant disease in high grade serous epithelial ovarian cancer

Project description:Introduction: Although High Grade Serous Ovarian Cancer (HGSOC) is considered a chemo-responsive disease, a proportion of patients do not respond to platinum-based chemotherapy at presentation or have progression-free survival of <6 months. Validated biomarkers of lack of response would enable alternative treatment stratification for these patients and identify novel mechanisms of resistance. Methods: Differential DNA methylation was investigated in independent tumour sets using Illumina 27K HumanMethylation arrays and validated by bisulphite pyrosequencing. Gene expression was by Affymetrix arrays and qRT-PCR. The role of Msh homeobox 1 (MSX1) in drug sensitivity was investigated by gene reintroduction into ovarian cancer cell lines. Results: CpG sites at contiguous genomic locations within the MSX1 gene have significantly lower levels of methylation in HGSOC which recur by 6 months compared to after 12 months and/or with RECIST response (p<0.05, q<0.05). A decrease in methylation at these intragenic CpG sites was significantly correlated with decreased MSX1 gene expression. Low expression of MSX1 was associated with poor progression-free survival independent of known clinical prognostic features (p=0.014). Three mutant or wild-type TP53 expressing ovarian cancer cell lines, resistant to cisplatin, have reduced MSX1 expression compared to matched parental, platinum sensitive, lines. Re-expression of MSX1 in resistant lines led to cisplatin sensitisation, increased apoptosis, increased p21 and BAX expression. However, in two TP53-null cell lines, MSX1 failed to change cisplatin sensitivity. Conclusion: Hypomethylation of MSX1 is a biomarker of resistant HGSOC disease at presentation and identifies a novel mechanism of platinum drug resistance. Bisulphite converted DNA from the 86 samples were hybridised to the Illumina Infinium 27k Human Methylation Beadchip v1.2

2015-11-26 | E-GEOD-75414 | biostudies-arrayexpress

Serological microRNAs as biomarkers for the diagnosis of adolescent tuberculosis infection in pleura

Project description:Serological microRNAs as biomarkers for the diagnosis of adolescent tuberculosis infection in pleura

| PRJNA745165 | ENA